Log in

Eidos Therapeutics Stock Forecast, Price & News

-1.21 (-1.68 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $70.92
50-Day Range
MA: $61.27
52-Week Range
Now: $70.92
Volume135,755 shs
Average Volume130,691 shs
Market Capitalization$2.74 billion
P/E RatioN/A
Dividend YieldN/A
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Read More
Eidos Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.07 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EIDX



Sales & Book Value

Annual Sales$26.69 million
Book Value$4.57 per share


Net Income$-37,830,000.00


Market Cap$2.74 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableNot Optionable
-1.21 (-1.68 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

How has Eidos Therapeutics' stock been impacted by Coronavirus?

Eidos Therapeutics' stock was trading at $43.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EIDX shares have increased by 61.6% and is now trading at $70.92.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Eidos Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Eidos Therapeutics

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Eidos Therapeutics

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics, Inc. (NASDAQ:EIDX) posted its earnings results on Thursday, October, 29th. The company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.71) by $0.08. The business had revenue of $0.13 million for the quarter.
View Eidos Therapeutics' earnings history

What price target have analysts set for EIDX?

10 brokers have issued 1-year price objectives for Eidos Therapeutics' shares. Their forecasts range from $34.00 to $80.00. On average, they expect Eidos Therapeutics' stock price to reach $60.58 in the next twelve months. This suggests that the stock has a possible downside of 14.6%.
View analysts' price targets for Eidos Therapeutics

Are investors shorting Eidos Therapeutics?

Eidos Therapeutics saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 809,400 shares, a decrease of 58.5% from the September 30th total of 1,950,000 shares. Based on an average daily trading volume, of 180,800 shares, the short-interest ratio is presently 4.5 days. Currently, 6.1% of the company's shares are short sold.
View Eidos Therapeutics' Short Interest

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), Crispr Therapeutics (CRSP), Aduro Biotech (ADRO), Micron Technology (MU), Pfizer (PFE), Verastem (VSTM), ImmunoGen (imgn), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY) and Axsome Therapeutics (AXSM).

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the following people:
  • Dr. Neil Kumar, CEO & Director (Age 41, Pay $247.68k)
  • Dr. Uma Sinha, Chief Scientific Officer & Director (Age 63, Pay $533.4k)
  • Dr. Cameron Turtle Ph.D., Chief Bus. Officer (Age 30, Pay $578.4k)
  • Dr. Jonathan C. Fox FACC, M.D., Ph.D., Pres & Chief Medical Officer (Age 63)
  • Dr. Isabella Graef M.D., Co-Founder & Board Advisor (Age 55)
  • Dr. Mamoun Alhamadsheh Ph.D., Pharm.D., Co-Founder
  • Mr. Franco Valle, Sr. VP of Fin., Principal Accounting Officer & Sec. (Age 39)
  • Matt Outten, Chief Commercial Officer
  • Dr. Hoyoung Huh, Consultant (Age 51)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

Who are Eidos Therapeutics' major shareholders?

Eidos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DekaBank Deutsche Girozentrale (0.04%) and BNP Paribas Arbitrage SA (0.01%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Cameron Turtle, Christine Siu, Eric Aguiar, Franco Valle, Jonathan C Fox and Uma Sinha.
View institutional ownership trends for Eidos Therapeutics

Which major investors are buying Eidos Therapeutics stock?

EIDX stock was purchased by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, and BNP Paribas Arbitrage SA. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, and Eric Aguiar.
View insider buying and selling activity for Eidos Therapeutics

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $70.92.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $2.74 billion and generates $26.69 million in revenue each year. The company earns $-37,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eidos Therapeutics employs 64 workers across the globe.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is www.eidostx.com.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.